-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA BIOSCIENCES AND SERVIER ANNOUNCE FIRST PATIENT DOSED IN OPTIMUM-11 GLOBAL PHASE 3 REGISTRATIONAL TRIAL OF DAROVASERTIB AND CRIZOTINIB AS ADJUVANT THERAPY FOR SUBJECTS WITH UVEAL MELANOMA

Reuters·09/09/2026 10:00:05

Please log in to view news